CA2794171A1 - Formes galeniques a liberation controlee pour des substances medicamenteuses hydrosolubles et hygroscopiques a dose elevee - Google Patents
Formes galeniques a liberation controlee pour des substances medicamenteuses hydrosolubles et hygroscopiques a dose elevee Download PDFInfo
- Publication number
- CA2794171A1 CA2794171A1 CA2794171A CA2794171A CA2794171A1 CA 2794171 A1 CA2794171 A1 CA 2794171A1 CA 2794171 A CA2794171 A CA 2794171A CA 2794171 A CA2794171 A CA 2794171A CA 2794171 A1 CA2794171 A1 CA 2794171A1
- Authority
- CA
- Canada
- Prior art keywords
- controlled release
- dosage form
- release dosage
- administration
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000013270 controlled release Methods 0.000 title claims abstract description 532
- 239000002552 dosage form Substances 0.000 title claims abstract description 327
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229940088679 drug related substance Drugs 0.000 title description 9
- 229940079593 drug Drugs 0.000 claims abstract description 258
- 239000003814 drug Substances 0.000 claims abstract description 258
- 239000000203 mixture Substances 0.000 claims abstract description 135
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 117
- 238000009472 formulation Methods 0.000 claims abstract description 111
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 239000012453 solvate Substances 0.000 claims abstract description 19
- 150000004677 hydrates Chemical class 0.000 claims abstract description 17
- 239000008199 coating composition Substances 0.000 claims description 99
- 238000000576 coating method Methods 0.000 claims description 86
- 239000011248 coating agent Substances 0.000 claims description 69
- VWYANPOOORUCFJ-UHFFFAOYSA-N alpha-Fernenol Chemical compound CC1(C)C(O)CCC2(C)C3=CCC4(C)C5CCC(C(C)C)C5(C)CCC4(C)C3CCC21 VWYANPOOORUCFJ-UHFFFAOYSA-N 0.000 claims description 64
- 229960003928 sodium oxybate Drugs 0.000 claims description 64
- 239000011148 porous material Substances 0.000 claims description 33
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 28
- 239000001856 Ethyl cellulose Substances 0.000 claims description 26
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 26
- 229920001249 ethyl cellulose Polymers 0.000 claims description 26
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 26
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 26
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 23
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 22
- 230000004888 barrier function Effects 0.000 claims description 22
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 22
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 18
- 229920005601 base polymer Polymers 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 14
- 239000000314 lubricant Substances 0.000 claims description 14
- 230000036470 plasma concentration Effects 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 229920001531 copovidone Polymers 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- -1 plasacryl Polymers 0.000 claims description 11
- 239000004014 plasticizer Substances 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 11
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 10
- 229920001983 poloxamer Polymers 0.000 claims description 10
- 239000000945 filler Substances 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 229940069328 povidone Drugs 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 235000000346 sugar Nutrition 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000005913 Maltodextrin Substances 0.000 claims description 5
- 229920002774 Maltodextrin Polymers 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 5
- 229940035034 maltodextrin Drugs 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 4
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 4
- 229910052744 lithium Inorganic materials 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 3
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- 240000007472 Leucaena leucocephala Species 0.000 claims description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229920002494 Zein Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 150000005215 alkyl ethers Chemical class 0.000 claims description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 229960000878 docusate sodium Drugs 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229940014259 gelatin Drugs 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 3
- 229940059904 light mineral oil Drugs 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 229940032147 starch Drugs 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 239000005019 zein Substances 0.000 claims description 3
- 229940093612 zein Drugs 0.000 claims description 3
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 229940096516 dextrates Drugs 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229920003124 powdered cellulose Polymers 0.000 claims description 2
- 235000019814 powdered cellulose Nutrition 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 150000001735 carboxylic acids Chemical class 0.000 claims 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims 2
- 229960001950 benzethonium chloride Drugs 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 2
- 229960002798 cetrimide Drugs 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 abstract description 7
- 229940127022 high-dose drug Drugs 0.000 abstract description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 78
- 239000003826 tablet Substances 0.000 description 68
- 238000011282 treatment Methods 0.000 description 54
- 239000000243 solution Substances 0.000 description 34
- 230000007958 sleep Effects 0.000 description 16
- 230000002459 sustained effect Effects 0.000 description 14
- 208000001640 Fibromyalgia Diseases 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- AZRRVLSHRWGNRS-UHFFFAOYSA-L calcium;4-hydroxybutanoate Chemical compound [Ca+2].OCCCC([O-])=O.OCCCC([O-])=O AZRRVLSHRWGNRS-UHFFFAOYSA-L 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 229940003856 sodium oxybate oral solution Drugs 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 description 5
- 201000003631 narcolepsy Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000007916 tablet composition Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000007939 sustained release tablet Substances 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 235000013522 vodka Nutrition 0.000 description 4
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000889 atomisation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000037053 non-rapid eye movement Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000001573 Cataplexy Diseases 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000011928 denatured alcohol Substances 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 229940051225 xyrem Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SQNWFKZOFAOCHM-UHFFFAOYSA-N 3-azaniumyl-2-methylprop-2-enoate Chemical class [NH3+]C=C(C)C([O-])=O SQNWFKZOFAOCHM-UHFFFAOYSA-N 0.000 description 1
- 229940006015 4-hydroxybutyric acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001489705 Aquarius Species 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010027590 Middle insomnia Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036649 mental concentration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000009498 subcoating Methods 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Abstract
La présente invention concerne des formes galéniques à libération contrôlée. Les formulations à libération contrôlée décrites dans ce document procurent une administration prolongée de médicaments à dose élevée qui sont hautement hydrosolubles et hautement hygroscopiques. Dans des modes de réalisation spécifiques, les formes galéniques à libération contrôlée sont destinées à l'administration d'un médicament choisi parmi le GHB et ses sels pharmaceutiquement acceptables, hydrates, tautomères, solvates et des complexes du GHB. Les formes galéniques à libération contrôlée décrites dans ce document peuvent incorporer des formulations à la fois à libération contrôlée et à libération immédiate dans une seule forme galénique unitaire.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31721210P | 2010-03-24 | 2010-03-24 | |
US61/317,212 | 2010-03-24 | ||
PCT/US2011/029802 WO2011119839A1 (fr) | 2010-03-24 | 2011-03-24 | Formes galéniques à libération contrôlée pour des substances médicamenteuses hydrosolubles et hygroscopiques à dose élevée |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2794171A1 true CA2794171A1 (fr) | 2011-09-29 |
CA2794171C CA2794171C (fr) | 2018-07-03 |
Family
ID=44673619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2794171A Active CA2794171C (fr) | 2010-03-24 | 2011-03-24 | Formes galeniques a liberation controlee pour des substances medicamenteuses hydrosolubles et hygroscopiques a dose elevee |
Country Status (10)
Country | Link |
---|---|
US (9) | US20120076865A1 (fr) |
EP (1) | EP2549987A4 (fr) |
JP (1) | JP5968300B2 (fr) |
CN (1) | CN102917697B (fr) |
AU (1) | AU2011232408B2 (fr) |
BR (1) | BR112012024019B1 (fr) |
CA (1) | CA2794171C (fr) |
IL (1) | IL222012A (fr) |
MX (2) | MX2020011961A (fr) |
WO (1) | WO2011119839A1 (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010011522A1 (fr) | 2008-07-21 | 2010-01-28 | Albemarle Corporation | Granulés d'ibuprofène sodique à teneur, leur préparation et leur utilisation dans la préparation de formes posologiques solides non effervescentes |
US8771735B2 (en) | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
US8778398B2 (en) * | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
US20120076865A1 (en) | 2010-03-24 | 2012-03-29 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
WO2014078014A2 (fr) | 2012-11-14 | 2014-05-22 | Metabolix, Inc. | Production de sels de 4-hydroxybutyrate à l'aide de matières premières biosourcées |
EP2931261A1 (fr) * | 2012-12-14 | 2015-10-21 | SI Group, Inc. | Granulés d'ibuprofène sodique à teneur élevée, leur préparation et leur utilisation dans la préparation de formes posologiques solides non effervescentes |
WO2014127053A2 (fr) | 2013-02-13 | 2014-08-21 | Metabolix, Inc. | Procédé de production d'un produit chimique ultrapur à partir de biomatériaux |
US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
US20150275167A1 (en) * | 2014-03-28 | 2015-10-01 | Corning Incorporated | Composition and method for cell culture sustained release |
HUE037945T2 (hu) * | 2014-07-09 | 2018-09-28 | Pf Medicament | Eljárás mozgási rendellenességek kezelésére befiradollal |
CA2910865C (fr) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions et methodes destines a reduire les surdoses |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
FR3049463B1 (fr) | 2016-04-01 | 2019-07-05 | Debregeas Et Associes Pharma | Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
WO2019126214A1 (fr) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Composition pharmaceutique comprenant des systèmes formant un radeau de rétention gastrique de ghb à libération de médicament par impulsions de déclenchement |
US11666546B2 (en) | 2017-12-18 | 2023-06-06 | Tris Pharma, Inc | GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
CA3086153A1 (fr) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Composition de poudre de medicament a liberation modifiee comprenant des systemes de formation de raft de retention gastrique ayant une liberation de medicament par impulsions de declenchement |
WO2019123269A1 (fr) * | 2017-12-20 | 2019-06-27 | Flamel Ireland Limited | Formulations conditionnées à libération modifiée de gamma-hydroxybutyrate ayant une stabilité améliorée |
AU2019383389A1 (en) * | 2018-11-19 | 2021-05-06 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
CA3127871A1 (fr) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Compositions de gamma-hydroxybutyrate presentant une pharmacocinetique amelioree a l'etat alimente |
EP4077262A1 (fr) | 2019-12-20 | 2022-10-26 | XWPharma Ltd. | Procédés de synthèse d'acide 4-valyloxybutyrique |
EP4167966A1 (fr) | 2020-06-18 | 2023-04-26 | XWPharma Ltd. | Granulations pharmaceutiques d'ingrédients pharmaceutiques actifs hydrosolubles |
CA3182394A1 (fr) * | 2020-06-18 | 2021-12-23 | Sami Karaborni | Granulations d'administration controlee de principes actifs pharmaceutiques hydrosolubles |
WO2022020621A1 (fr) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Compositions pharmaceutiques et pharmacocinétiques d'un dérivé de l'acide gamma-hydroxybutyrique |
TW202228665A (zh) | 2020-10-05 | 2022-08-01 | 凱瑞康寧生技股份有限公司 | γ-羥基丁酸衍生物之修飾釋放組合物 |
CA3195856A1 (fr) | 2020-10-16 | 2022-04-21 | Franck SKOBIERANDA | Methodes de traitement utilisant ghb |
TW202300139A (zh) | 2021-03-19 | 2023-01-01 | 凱瑞康寧生技股份有限公司 | γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學 |
WO2023062018A1 (fr) | 2021-10-11 | 2023-04-20 | Jazz Pharmaceuticals Ireland Limited | Procédé d'administration d'oxybate |
WO2023135150A1 (fr) | 2022-01-11 | 2023-07-20 | Jazz Pharmaceuticals Ireland Limited | Procédé d'administration d'oxybate |
US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB922029A (en) | 1960-05-19 | 1963-03-27 | Equilibre Biolog L | Therapeutic composition |
US3051619A (en) | 1960-05-19 | 1962-08-28 | Equilibre Biolog L | 4-hydroxy butyric acid therapeutic compositions and process of use for clinical sedation, hypnosis, or anaesthesia |
DE1642902A1 (de) | 1965-09-30 | 1971-05-19 | Unilever Nv | Verfahren zur kontinuierlichen Entsaeuerung von Glyceridoelen |
US4221778A (en) | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
US4374441A (en) | 1980-05-23 | 1983-02-22 | Book Covers, Inc. | Method of making a book cover and pocket element therefor |
ZA814854B (en) | 1980-07-17 | 1982-07-28 | J Klosa | Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts |
EP0044801B1 (fr) | 1980-07-17 | 1984-02-15 | Josef Dr. Klosa | Sels non hygroscopiques de l'acide 4-hydroxybutyrique, procédé pour leur préparation et leur utilisation pour la fabrication des agents pharmaceutiques |
CH655507B (fr) | 1983-01-12 | 1986-04-30 | ||
US4524217A (en) | 1984-06-08 | 1985-06-18 | Celanese Corporation | Process for producing N-acyl-hydroxy aromatic amines |
EP0235408B1 (fr) | 1984-08-06 | 1991-01-09 | The University Of Toronto Innovations Foundation | Composition pharmaceutique et traitement |
US4687662A (en) | 1985-08-30 | 1987-08-18 | Warner-Lambert Company | Therapeutic effervescent composition |
IE59106B1 (en) | 1985-05-31 | 1994-01-12 | Warner Lambert Co | A therapeutic effervescent composition and a method of preparing the same |
US4738985A (en) | 1986-03-19 | 1988-04-19 | The University Of Toronto Innovations Foundations | Pharmaceutical composition and treatment |
DE3804168A1 (de) | 1988-02-11 | 1989-08-24 | Gewerk Eisenhuette Westfalia | Planetenueberlagerungsgetriebe und ueberlagerungsantrieb fuer kettenbaender u. dgl., insbesondere fuer kettenfoerderer und kettengezogene bergbau-gewinnungsmaschinen |
IT1217783B (it) | 1988-06-03 | 1990-03-30 | Farmaceutico Ct S R L Lab | Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative |
US5294430A (en) | 1988-09-12 | 1994-03-15 | University Of Rochester | Use of dithiocarbamates to treat myelosuppression |
US4916161A (en) | 1988-10-25 | 1990-04-10 | Bristol-Myers Squibb | Taste-masking pharmaceutical agents |
JP2564690B2 (ja) | 1990-06-14 | 1996-12-18 | 三省製薬 株式会社 | メラニン生成抑制外用剤 |
DE4113984C2 (de) | 1991-04-29 | 2002-05-08 | Koehler Chemie Dr Franz | Salze der 4-Hydroxy-Buttersäure |
US5415870A (en) | 1991-07-01 | 1995-05-16 | Gerhard Gergely | Effervescent systems using reaction doping agents |
IT1271403B (it) | 1993-03-26 | 1997-05-28 | Ct Lab Farm Srl | Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi |
DE69405752T2 (de) | 1993-06-14 | 1998-02-05 | Janssen Pharmaceutica Nv | Filmbeschichtete tablette von astemizol und pseudoephedrin mit verlängerter freigabe |
IT1266565B1 (it) * | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
US5833599A (en) | 1993-12-13 | 1998-11-10 | Multum Information Services | Providing patient-specific drug information |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US7072840B1 (en) | 1994-10-28 | 2006-07-04 | Cybear, L.L.C. | Prescription management system |
US5845255A (en) | 1994-10-28 | 1998-12-01 | Advanced Health Med-E-Systems Corporation | Prescription management system |
GB9423542D0 (en) | 1994-11-22 | 1995-01-11 | Marples Brian A | Pharmaceutical compounds |
JP4072597B2 (ja) * | 1994-12-27 | 2008-04-09 | ナムローゼ・フェンノートシャップ・オルガノン | 持続性製剤 |
US5758095A (en) | 1995-02-24 | 1998-05-26 | Albaum; David | Interactive medication ordering system |
US5840331A (en) | 1995-06-07 | 1998-11-24 | Arch Development Corporation | Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin |
US6112182A (en) | 1996-01-16 | 2000-08-29 | Healthcare Computer Corporation | Method and apparatus for integrated management of pharmaceutical and healthcare services |
IT1283782B1 (it) | 1996-08-09 | 1998-04-30 | Ct Lab Farm Srl | Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo |
US20080292700A1 (en) * | 1997-04-21 | 2008-11-27 | Biovail Laboratories | Controlled release formulations using intelligent polymers |
US5990162A (en) | 1997-08-29 | 1999-11-23 | Orphan Medical, Inc. | Method for treatment of fibromyalgia and chronic fatigue syndrome |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6472432B1 (en) | 1997-11-17 | 2002-10-29 | Nicholas V. Perricone | Treatment of rosacea using lipoic acid |
US6014631A (en) | 1998-04-02 | 2000-01-11 | Merck-Medco Managed Care, Llc | Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry |
US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
EP1316309A1 (fr) | 1998-12-23 | 2003-06-04 | Orphan Medical Inc. | Solutions de sels d'hydroxybutyrate stables et saines au plan microbiologique,pour le traitement de la narcolepsie |
DE69907508T2 (de) | 1998-12-23 | 2003-11-20 | Orphan Medical Inc | Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten |
US6067524A (en) | 1999-01-07 | 2000-05-23 | Catalina Marketing International, Inc. | Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data |
US6565872B2 (en) | 1999-02-16 | 2003-05-20 | Xiao Yu Wu | Polymeric system for drug delivery and solute separation |
US6384020B1 (en) | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
EP1325014B1 (fr) | 2000-09-22 | 2012-05-23 | JPI Commercial, LLC | Compositions de gamma-hydroxybutyrate contenant des excipients glucides |
WO2002045684A2 (fr) | 2000-12-06 | 2002-06-13 | Pharmacia Corporation | Composition pharmaceutique a dispersion rapide |
FR2830447B1 (fr) | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US20030180249A1 (en) | 2002-03-18 | 2003-09-25 | Khanna Satish Chandra | Dosage forms for hygroscopic active ingredients |
US8216609B2 (en) * | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
RU2210360C1 (ru) | 2002-09-19 | 2003-08-20 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Психотропное средство |
US7668730B2 (en) | 2002-12-17 | 2010-02-23 | JPI Commercial, LLC. | Sensitive drug distribution system and method |
ATE482699T1 (de) | 2002-12-23 | 2010-10-15 | Merck Frosst Company | Pharmazeutische zusammensetzungen und verfahren zur behandlung von morbus parkinson |
US20050031688A1 (en) | 2003-08-04 | 2005-02-10 | Ayala William J. | Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration |
ATE454138T1 (de) * | 2003-08-08 | 2010-01-15 | Biovail Lab Int Srl | Tablette mit modifizierter freisetzung von bupropion hydrochlorid |
JP2007501810A (ja) | 2003-08-11 | 2007-02-01 | メルク フロスト カナダ リミテツド | 一段階被覆法を用いて作製された着香味遮蔽製薬製剤 |
US20050142192A1 (en) | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
CA2579576A1 (fr) | 2004-09-07 | 2006-03-16 | Orphan Medical, Inc. | Compositions ghb ameliorees |
US8193211B2 (en) | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
AR051397A1 (es) | 2004-10-21 | 2007-01-10 | Novartis Ag | Composicion farmaceutica |
CA2586975A1 (fr) | 2004-11-10 | 2006-05-18 | The Trustees Of Columbia University In The City Of New York | Methode de traitement de troubles moteurs |
AU2005325930B2 (en) | 2005-01-27 | 2012-01-19 | Alembic Limited | Extended release formulation of Levetiracetam |
FR2881652B1 (fr) | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
WO2006124609A2 (fr) | 2005-05-16 | 2006-11-23 | Joseph Johnson | Procedes et compositions pour le traitement de l'arg |
US7645802B2 (en) * | 2005-06-27 | 2010-01-12 | Biovail Laboratories International Srl. | Bupropion hydrobromide and therapeutic applications |
EP1909769A2 (fr) | 2005-08-01 | 2008-04-16 | Alpharma, Inc. | Formulations pharmaceutiques resistantes a l'alcool |
PL116330U1 (en) | 2005-10-31 | 2007-04-02 | Alza Corp | Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation |
US20090317355A1 (en) | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
US20070264346A1 (en) | 2006-02-16 | 2007-11-15 | Flamel Technologies | Multimicroparticulate pharmaceutical forms for oral administration |
US8309104B2 (en) | 2006-03-02 | 2012-11-13 | Watson Pharmaceuticals, Inc. | Oral controlled release formulation for sedative and hypnotic agents |
EP2018160B1 (fr) | 2006-03-16 | 2011-12-14 | Tris Pharma, Inc. | Formulations a liberation modifiee contenant des complexes medicament - resine echangeuse d'ions |
US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
EP2068840A2 (fr) * | 2006-07-21 | 2009-06-17 | LAB International SRL | Système de délivrance hydrophobe empêchant les utilisations abusives |
US20080085304A1 (en) | 2006-10-10 | 2008-04-10 | Penwest Pharmaceuticals Co. | Robust sustained release formulations |
US8394845B2 (en) | 2006-10-30 | 2013-03-12 | Hanall Biopharma Co., Ltd. | Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor |
KR20090088913A (ko) | 2006-11-21 | 2009-08-20 | 맥네일-피피씨, 인코포레이티드 | 개질된 방출형 진통 현탁제 |
US20100291205A1 (en) | 2007-01-16 | 2010-11-18 | Egalet A/S | Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse |
US7568822B2 (en) | 2007-03-28 | 2009-08-04 | Visteon Global Technologies, Inc. | Predictive adaptive front lighting algorithm for branching road geometry |
US8202542B1 (en) | 2007-05-31 | 2012-06-19 | Tris Pharma | Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings |
GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
US8771735B2 (en) * | 2008-11-04 | 2014-07-08 | Jazz Pharmaceuticals, Inc. | Immediate release dosage forms of sodium oxybate |
US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
FR2938431B1 (fr) | 2008-11-14 | 2013-12-20 | Debregeas Et Associes Pharma | Nouvelle composition a base d'acide gamma-hydroxybutyrique |
SI2421808T1 (sl) | 2009-04-23 | 2013-12-31 | Concert Pharmaceuticals Inc. | Analogi 4-hidroksi maslene kisline |
FR2951378B1 (fr) | 2009-10-16 | 2012-06-01 | Flamel Tech Sa | Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee |
US20120076865A1 (en) | 2010-03-24 | 2012-03-29 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
CN102905688B (zh) | 2010-04-06 | 2015-11-25 | 阿勒根公司 | 用于前房内药物递送的缓释储库式植入物 |
AU2011237612B2 (en) | 2010-04-07 | 2016-05-12 | Otsuka Pharmaceutical Co., Ltd. | Miniature ingestible device |
EP2386289A1 (fr) | 2010-04-29 | 2011-11-16 | Ipsen Pharma S.A.S. | Compositions d'argile |
CN102946869B (zh) | 2010-05-04 | 2016-08-03 | 爵士制药有限公司 | γ-羟基丁酸的速释制剂及剂型 |
EP3146972A1 (fr) | 2010-05-07 | 2017-03-29 | Microdermis Corporation | Composition topique comprenant de la povidone iodée |
ES2792799T3 (es) | 2010-06-28 | 2020-11-12 | Merck Patent Gmbh | [1,8]naftiridinas 2,4-diaril-sustituidas como inhibidores de quinasas para su uso contra el cáncer |
GB201014633D0 (en) | 2010-09-02 | 2010-10-13 | Avexxin As | Rheumatoid arthritis treatment |
US8617602B2 (en) | 2010-09-03 | 2013-12-31 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments |
PL2623498T3 (pl) | 2010-09-30 | 2016-05-31 | Toyama Chemical Co Ltd | Sól sodowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu |
HUE026794T2 (en) | 2010-09-30 | 2016-07-28 | Toyama Chemical Co Ltd | The oleum salt of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
US20130230587A1 (en) | 2010-11-10 | 2013-09-05 | Rubicon Research Private Limited | Sustained release compositions |
US20140141090A1 (en) | 2011-02-02 | 2014-05-22 | Edward S. Wilson | Pharmaceutical Composition Comprising Opioid Agonist And Sequestered Antagonist |
FR2971422B1 (fr) | 2011-02-11 | 2016-05-20 | Debregeas Et Associes Pharma | Granules d'acide gamma-hydroxybutyrique |
KR101976218B1 (ko) | 2011-02-14 | 2019-05-07 | 콘서트 파마슈티컬즈, 인크. | 4-히드록시부티르산 중수소화 유사체 |
RU2013147744A (ru) | 2011-04-15 | 2015-05-20 | Тресхолд Фармасьютикалз, Инк. | Дозированная лекарственная форма для перорального применения |
EP2760911B1 (fr) | 2011-09-27 | 2017-11-22 | Tepha, Inc. | Hydrolyse contrôlée de poly-4-hydroxybutyrate et copolymères |
WO2014078014A2 (fr) | 2012-11-14 | 2014-05-22 | Metabolix, Inc. | Production de sels de 4-hydroxybutyrate à l'aide de matières premières biosourcées |
FR2999426B1 (fr) | 2012-12-13 | 2015-01-02 | Flamel Tech Sa | Forme orale multiparticulaire a liberation immediate d'au moins un compose actif, comprenant des particules enrobees resistantes au broyage. |
US8591922B1 (en) | 2012-12-14 | 2013-11-26 | Jazz Pharmacuticals, Inc. | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
US9050302B2 (en) | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
US20150005334A1 (en) | 2013-03-15 | 2015-01-01 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9801852B2 (en) | 2013-08-30 | 2017-10-31 | Jazz Pharmaceuticals, Inc. | Devices and methods for facilitating and controlling use of a medication |
US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
JP6338683B2 (ja) | 2014-02-06 | 2018-06-06 | シーケンシャル メディシン リミテッド | 睡眠を補助する組成物及び方法 |
WO2015120110A2 (fr) | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Nouvelles formulations pharmaceutiques |
US9962336B2 (en) | 2014-05-01 | 2018-05-08 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
US20160317388A1 (en) | 2014-05-01 | 2016-11-03 | Sun Pharmaceutical Industries Limited | Dual-chamber pack for extended release suspension compositions |
AU2015254875A1 (en) | 2014-05-01 | 2016-11-17 | Sun Pharmaceutical Industries Limited | Extended release suspension compositions |
MA41124A (fr) | 2014-12-05 | 2017-10-10 | Sun Pharmaceutical Ind Ltd | Compositions en suspension à libération prolongée à rétention gastrique |
US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
EP3288518A4 (fr) | 2015-05-01 | 2018-12-12 | Sun Pharmaceutical Industries Limited | Emballage à deux chambres pour compositions de suspension à libération prolongée |
CA3207586A1 (fr) | 2016-02-24 | 2017-08-31 | Chemapotheca, Llc | Liberation controlee de l'amphetamine, promedicament et formes posologiques dissuasives du mesusage |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
WO2019123269A1 (fr) | 2017-12-20 | 2019-06-27 | Flamel Ireland Limited | Formulations conditionnées à libération modifiée de gamma-hydroxybutyrate ayant une stabilité améliorée |
AU2019383389A1 (en) | 2018-11-19 | 2021-05-06 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
CA3127871A1 (fr) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Compositions de gamma-hydroxybutyrate presentant une pharmacocinetique amelioree a l'etat alimente |
KR20220119429A (ko) | 2019-12-24 | 2022-08-29 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 감마-히드록시부티레이트(ghb) 투약 |
-
2011
- 2011-03-24 US US13/071,369 patent/US20120076865A1/en not_active Abandoned
- 2011-03-24 JP JP2013501486A patent/JP5968300B2/ja active Active
- 2011-03-24 BR BR112012024019-6A patent/BR112012024019B1/pt active IP Right Grant
- 2011-03-24 EP EP11760221.9A patent/EP2549987A4/fr active Pending
- 2011-03-24 MX MX2020011961A patent/MX2020011961A/es unknown
- 2011-03-24 AU AU2011232408A patent/AU2011232408B2/en active Active
- 2011-03-24 CA CA2794171A patent/CA2794171C/fr active Active
- 2011-03-24 CN CN201180025543.3A patent/CN102917697B/zh active Active
- 2011-03-24 MX MX2012011022A patent/MX2012011022A/es active IP Right Grant
- 2011-03-24 WO PCT/US2011/029802 patent/WO2011119839A1/fr active Application Filing
-
2012
- 2012-09-20 IL IL222012A patent/IL222012A/en active IP Right Grant
-
2018
- 2018-07-02 US US16/025,487 patent/US10758488B2/en active Active
-
2019
- 2019-12-12 US US16/712,260 patent/US10987310B2/en active Active
-
2020
- 2020-06-30 US US16/916,677 patent/US10813885B1/en active Active
- 2020-09-04 US US17/012,823 patent/US10959956B2/en active Active
- 2020-09-04 US US17/012,831 patent/US10966931B2/en active Active
-
2021
- 2021-04-07 US US17/224,781 patent/US11090269B1/en active Active
- 2021-07-20 US US17/380,509 patent/US11207270B2/en active Active
- 2021-12-13 US US17/549,151 patent/US20220096384A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10987310B2 (en) | 2021-04-27 |
US10813885B1 (en) | 2020-10-27 |
US20200330389A1 (en) | 2020-10-22 |
EP2549987A1 (fr) | 2013-01-30 |
IL222012A (en) | 2017-11-30 |
US20180318222A1 (en) | 2018-11-08 |
AU2011232408A1 (en) | 2012-10-11 |
US11090269B1 (en) | 2021-08-17 |
JP5968300B2 (ja) | 2016-08-10 |
MX2012011022A (es) | 2013-02-26 |
US10966931B2 (en) | 2021-04-06 |
BR112012024019B1 (pt) | 2021-10-19 |
US20200397706A1 (en) | 2020-12-24 |
CA2794171C (fr) | 2018-07-03 |
CN102917697B (zh) | 2016-01-20 |
JP2013522373A (ja) | 2013-06-13 |
WO2011119839A1 (fr) | 2011-09-29 |
EP2549987A4 (fr) | 2015-01-21 |
US20200397705A1 (en) | 2020-12-24 |
US20220096384A1 (en) | 2022-03-31 |
US20210244670A1 (en) | 2021-08-12 |
US20200113840A1 (en) | 2020-04-16 |
BR112012024019A2 (pt) | 2016-08-30 |
AU2011232408B2 (en) | 2015-07-30 |
US10959956B2 (en) | 2021-03-30 |
US20210346300A1 (en) | 2021-11-11 |
MX2020011961A (es) | 2022-04-19 |
CN102917697A (zh) | 2013-02-06 |
US20120076865A1 (en) | 2012-03-29 |
US10758488B2 (en) | 2020-09-01 |
US11207270B2 (en) | 2021-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11207270B2 (en) | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances | |
JP5816091B2 (ja) | ナトリウムオキシベートの即時放出投薬形態 | |
WO2011111818A1 (fr) | Mosapride et composition médicinale à libération lente comprenant un sel de mosapride | |
AU2003260336B2 (en) | Sustained release formulations comprising lamotrigine | |
JP6976946B2 (ja) | 生理活性の強い、urat1のインヒビターを含む医薬組成物 | |
AU2010352575A1 (en) | Immediate release formulations and dosage forms of gamma-hydroxybutyrate | |
NZ537885A (en) | Sustained release formulations comprising a lamotrigine core and an outer coating | |
WO2009027786A2 (fr) | Formes posologiques matricielles de varénicline | |
WO2011064797A2 (fr) | Compositions pharmaceutiques à libération contrôlée de galantamine | |
EP3796908B1 (fr) | Formulations de propivérine à libération contrôlée | |
WO2023044024A1 (fr) | Nouveau système d'administration de médicament à revêtement dépendant du ph | |
US20120064161A1 (en) | Modified release niacin pharmaceutical formulations | |
WO2010134938A1 (fr) | Formulations pharmaceutiques à base de niacine à libération modifiée |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20160323 |